Table 2

Characteristics of thromboembolic events after ICI initiation

N (%)
VTE37 (16.2)
 Deep vein thrombosis17 (46.0)
 PE9 (24.3)
 Visceral vein thrombosis2 (5.4)
 Deep vein thrombosis+PE8 (21.6)
 Deep vein thrombosis+visceral vein thrombosis1 (2.7)
ICI type(s)
 Ipilimumab7 (18.9)
 Ipilimumab/nivolumab16 (43.2)
 Nivolumab3 (8.1)
 Pembrolizumab11 (29.7)
Hospitalized for VTE23 (62.2)
Hospitalized within 30 days before VTE9 (24.3)
ICI stopped after VTE9 (24.3)
ICI delayed after VTE5 (13.5)
Death as result of VTE1 (2.7)
ATE14 (6.1)
 MI5 (35.7)
 Stroke8 (57.2)
 TIA1 (7.1)
ICI type(s)
 Ipilimumab3 (21.4)
 Ipilimumab/nivolumab3 (21.4)
 Nivolumab1 (7.1)
 Pembrolizumab7 (50.0)
Hospitalized for ATE11 (78.6)
Hospitalized within 30 days before ATE5 (35.7)
ICI stopped after ATE4 (28.6)
ICI delayed after ATE2 (14.3)
Death as result of ATE6 (43.0)
  • ATE, arterial thromboembolism; ICI, immune checkpoint inhibitor; MI, myocardial infarction; PE, pulmonary embolism; TIA, transient ischemic attack; VTE, venous thromboembolism.